Trial Profile

A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Idarubicin (Primary)
Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions

Most Recent Events

06 Jun 2017 Status changed from active, no longer recruiting to completed.
03 Dec 2016 This trial has been completed in France (end date: 9 May 2016).
28 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com